Dataset Information

Development of an artificial intelligence-based diagnostic model for Alzheimer's disease.

ABSTRACT:

Introduction

The diagnosis of Alzheimer's disease (AD) is sometimes difficult for nonspecialists, resulting in misdiagnosis. A missed diagnosis can lead to improper management and poor outcomes. Moreover, nonspecialists lack a simple diagnostic model with high accuracy for AD diagnosis.

Methods

Randomly assigned data, including training data, of 6000 patients and test data of 1932 from 7932 patients who visited our memory clinic between 2009 and 2021 were introduced into the artificial intelligence (AI)-based AD diagnostic model, which we had developed.

Results

The AI-based AD diagnostic model used age, sex, Hasegawa's Dementia Scale-Revised, the Mini-Mental State Examination, the educational level, and the voxel-based specific regional analysis system for Alzheimer's disease (VSRAD) score. It had a sensitivity, specificity, and c-static value of 0.954, 0.453, and 0.819, respectively. The other AI-based model that did not use the VSRAD had a sensitivity, specificity, and c-static value of 0.940, 0.504, and 0.817, respectively.

Discussion

We created an AD diagnostic model with high sensitivity for AD diagnosis using only data acquired in daily clinical practice. By using these AI-based models, nonspecialists could reduce missed diagnoses and contribute to the appropriate use of medical resources.

SUBMITTER: Fujita K

PROVIDER: S-EPMC9549305 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Development of an artificial intelligence-based diagnostic model for Alzheimer's disease.

Fujita Kazuki K Katsuki Masahito M Takasu Ai A Kitajima Ayako A Shimazu Tomokazu T Maruki Yuichi Y

Aging medicine (Milton (N.S.W)) 20220925 3

<h4>Introduction</h4>The diagnosis of Alzheimer's disease (AD) is sometimes difficult for nonspecialists, resulting in misdiagnosis. A missed diagnosis can lead to improper management and poor outcomes. Moreover, nonspecialists lack a simple diagnostic model with high accuracy for AD diagnosis.<h4>Methods</h4>Randomly assigned data, including training data, of 6000 patients and test data of 1932 from 7932 patients who visited our memory clinic between 2009 and 2021 were introduced into the artif ...[more]

PMID: 36247338

Similar Datasets

Project description:BackgroundBronchoscopy is a key step in the diagnosis and treatment of respiratory diseases. However, the level of expertise varies among different bronchoscopists. Artificial intelligence (AI) may help them identify bronchial lumens. Thus, a bronchoscopy quality-control system based on AI was built to improve the performance of bronchoscopists.MethodsThis single-center observational study consecutively collected bronchoscopy videos from Shanghai Chest Hospital and segmented each video into 31 different anatomical locations to develop an AI-assisted system based on a convolutional neural network (CNN) model. We then designed a single-center trial to compare the accuracy of lumen recognition by bronchoscopists with and without the assistance of the AI system.ResultsA total of 28,441 qualified images of bronchial lumen were used to train the CNNs. In the cross-validation set, the optimal accuracy of the six models was between 91.83% and 96.62%. In the test set, the visual geometry group 16 (VGG-16) achieved optimal performance with an accuracy of 91.88%, and an area under the curve of 0.995. In the clinical evaluation, the accuracy rate of the AI system alone was 54.30% (202/372). For the identification of bronchi except for segmental bronchi, the accuracy was 82.69% (129/156). In group 1, the recognition accuracy rates of doctors A, B, a and b alone were 42.47%, 34.68%, 28.76%, and 29.57%, respectively, but increased to 57.53%, 54.57%, 54.57%, and 46.24% respectively when combined with the AI system. Similarly, in group 2, the recognition accuracy rates of doctors C, D, c, and d were 37.90%, 41.40%, 30.91%, and 33.60% respectively, but increased to 51.61%, 47.85%, 53.49%, and 54.30% respectively, when combined with the AI system. Except for doctor D, the accuracy of doctors in recognizing lumen was significantly higher with AI assistance than without AI assistance, regardless of their experience (P<0.001).ConclusionsOur AI system could better recognize bronchial lumen and reduce differences in the operation levels of different bronchoscopists. It could be used to improve the quality of everyday bronchoscopies.

Project description:Alzheimer's disease (AD) is the most common type of dementia. Its diagnosis and progression detection have been intensively studied. Nevertheless, research studies often have little effect on clinical practice mainly due to the following reasons: (1) Most studies depend mainly on a single modality, especially neuroimaging; (2) diagnosis and progression detection are usually studied separately as two independent problems; and (3) current studies concentrate mainly on optimizing the performance of complex machine learning models, while disregarding their explainability. As a result, physicians struggle to interpret these models, and feel it is hard to trust them. In this paper, we carefully develop an accurate and interpretable AD diagnosis and progression detection model. This model provides physicians with accurate decisions along with a set of explanations for every decision. Specifically, the model integrates 11 modalities of 1048 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) real-world dataset: 294 cognitively normal, 254 stable mild cognitive impairment (MCI), 232 progressive MCI, and 268 AD. It is actually a two-layer model with random forest (RF) as classifier algorithm. In the first layer, the model carries out a multi-class classification for the early diagnosis of AD patients. In the second layer, the model applies binary classification to detect possible MCI-to-AD progression within three years from a baseline diagnosis. The performance of the model is optimized with key markers selected from a large set of biological and clinical measures. Regarding explainability, we provide, for each layer, global and instance-based explanations of the RF classifier by using the SHapley Additive exPlanations (SHAP) feature attribution framework. In addition, we implement 22 explainers based on decision trees and fuzzy rule-based systems to provide complementary justifications for every RF decision in each layer. Furthermore, these explanations are represented in natural language form to help physicians understand the predictions. The designed model achieves a cross-validation accuracy of 93.95% and an F1-score of 93.94% in the first layer, while it achieves a cross-validation accuracy of 87.08% and an F1-Score of 87.09% in the second layer. The resulting system is not only accurate, but also trustworthy, accountable, and medically applicable, thanks to the provided explanations which are broadly consistent with each other and with the AD medical literature. The proposed system can help to enhance the clinical understanding of AD diagnosis and progression processes by providing detailed insights into the effect of different modalities on the disease risk.

Project description:Background: There are no obvious clinical signs and symptoms in the early stages of Alzheimer's disease (AD), and most patients usually have mild cognitive impairment (MCI) before diagnosis. Therefore, early diagnosis of AD is very critical. This paper mainly discusses the blood biomarkers of AD patients and uses machine learning methods to study the changes of blood transcriptome during the development of AD and to search for potential blood biomarkers for AD. Methods: Individualized blood mRNA expression data of 711 patients were downloaded from the GEO database, including the control group (CON) (238 patients), MCI (189 patients), and AD (284 patients). Firstly, we analyzed the subcellular localization, protein types and enrichment pathways of the differentially expressed mRNAs in each group, and established an artificial intelligence individualized diagnostic model. Furthermore, the XCell tool was used to analyze the blood mRNA expression data and obtain blood cell composition and quantitative data. Ratio characteristics were established for mRNA and XCell data. Feature engineering operations such as collinearity and importance analysis were performed on all features to obtain the best feature solicitation. Finally, four machine learning algorithms, including linear support vector machine (SVM), Adaboost, random forest and artificial neural network, were used to model the optimal feature combinations and evaluate their classification performance in the test set. Results: Through feature engineering screening, the best feature collection was obtained. Moreover, the artificial intelligence individualized diagnosis model established based on this method achieved a classification accuracy of 91.59% in the test set. The area under curve (AUC) of CON, MCI, and AD were 0.9746, 0.9536, and 0.9807, respectively. Conclusion: The results of cell homeostasis analysis suggested that the homeostasis of Natural killer T cell (NKT) might be related to AD, and the homeostasis of Granulocyte macrophage progenitor (GMP) might be one of the reasons for AD.

Dataset Information

Development of an artificial intelligence-based diagnostic model for Alzheimer's disease.

Introduction

Methods

Results

Discussion

Publications

Development of an artificial intelligence-based diagnostic model for Alzheimer's disease.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets